NSRGF Stock Recent News

Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple medically vulnerable patient populations at high risk of life-threatening bacterial infections

GENEVA--(BUSINESS WIRE)--Lucien Selce and MKT Capital Ltd. (together, “we”), who collectively own 1.4 million shares of Seres Therapeutics Inc. (NASDAQ: MCRB) (“Seres” or the “Company”), today published the following open letter to the Company's Board of Directors (the “Board”). *** September 27, 2024 Members of the Board, We are writing to you today as a stockholder of Seres who is seeking additional information regarding the Company's planned sale of its VOWST business to Nestlé Health Scienc.

Nestle has replaced its CEO Mark Schneider with company veteran Laurent Freixe in a bid to shake up its fortunes. The Swiss firm said in a statement Thursday that Schneider, who was at the helm for eight years, "has decided to relinquish his roles as CEO and member of the board of directors.

Nestle shares slumped Friday after the food giant abruptly announced the departure of its chief executive.

Britain's competition watchdog has decided not to pursue its probe into the infant formula and follow-on milk market, despite identifying a range of concerns. According to the Competition and Markets Authority, the combination of regulation, manufacturer behaviour, and customer needs has led to poor market outcomes.

Upon closing, Seres to receive $175M cash infusion, including an upfront payment, prepayment of a future commercial milestone payment, and an equity investment in Seres common stock, less approximately $20M in settlement of net obligations between the Parties; anticipated deal closing in the next 90 days

Swiss consumer brands behemoth Nestlé S.A. sparked a share sell off on Thursday after slashing its full-year sales guidance.

Transaction ensures Nestlé Health Science will continue to commercialize the product BRIDGEWATER, N.J. , June 6, 2024 /PRNewswire/ -- Seres Therapeutics, Inc. (Nasdaq: MCRB), announced today that it has agreed to a non-binding memorandum of understanding with Nestlé Health Science in which Nestlé Health Science will acquire certain tangible and intangible assets associated with VOWST (fecal microbiota spores, live-brpk) capsules.

Nestlé is launching a line of food products tailored to people using weight-loss medication in an effort to capitalize on a market expected to reach $30 billion in the next six years.

Nestlé is launching a frozen food brand specifically aimed at people taking GLP-1 diabetes and weight loss drugs like Ozempic and Wegovy, the company announced Tuesday, part of the food giant's wider strategy to offset potential sales losses as appetite-suppressing drugs grow popular.